EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CEL-SCI's enterprise value is €69.50 Mil.
CEL-SCI's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, CEL-SCI's EV-to-Revenue for today is .
The historical rank and industry rank for CEL-SCI's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of CEL-SCI was 8.12. The lowest was -73.22. And the median was -1.38.
FRA:LSRM's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.155 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-21), CEL-SCI's stock price is €1.165.
CEL-SCI's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, CEL-SCI's PS Ratio for today is .
CEL-SCI EV-to-Revenue Historical Data
The historical data trend for CEL-SCI's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CEL-SCI's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CEL-SCI's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CEL-SCI's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CEL-SCI's EV-to-Revenue falls into.
CEL-SCI's current Enterprise Value is €69.50 Mil.
CEL-SCI's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CEL-SCI's share price for today is €1.165.
CEL-SCI's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CEL-SCI EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CEL-SCI's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:LSRM has been successfully added to your 